SM
NGNE icon

Sabby Management’s Neurogene NGNE Stock Holding History

Sabby Management’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-2,760
Closed -$146K – 139
2018
Q2 		$146K Buy
+2,760
New +$719K 0.02% 107
2016
Q1 		– Sell
-3,016
Closed -$753K – 336
2015
Q4 		$753K Buy
3,016
+16
+0.5% +$4.21K 0.04% 209
2015
Q3 		$844K Buy
+3,000
New +$691K 0.03% 256

Other funds holding NGNE

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Sabby Management's NGNE Position: Q3 2018 in Review

Sabby Management sold out of Neurogene (NGNE) in Q3 2018, closing a stake of 2,760 shares — an estimated $146K sold.

Sabby Management first reported a position in NGNE in Q3 2015 and held it in 3 quarters. The position peaked at $844K in Q3 2015. 45 funds tracked by Wall St. Rank hold NGNE as of Q3 2018.

  • Sabby Management reported no remaining Neurogene position as of Q3 2018 after selling out during the quarter.
  • Sabby Management sold 2,760 Neurogene shares in Q3 2018, an estimated $146K.
  • Sabby Management first reported a position in Neurogene in Q3 2015 and held it in 3 quarters.
  • Sabby Management's Neurogene position peaked at $844K in Q3 2015.
  • 45 funds tracked by Wall St. Rank held Neurogene as of Q3 2018.

Based on Sabby Management's 13F filing for Q3 2018, filed 14 Nov 2018.